Yang Li-Qun, Li Shen-Jing, Cao Yun-Fei, Man Xiao-Bo, Yu Wei-Feng, Wang Hong-Yang, Wu Meng-Chao
Department of Anesthesiology, Eastern Hepatobiliary Surgery Hospital, the Second Military Medical University, Shanghai 200438, China.
World J Gastroenterol. 2003 Feb;9(2):359-63. doi: 10.3748/wjg.v9.i2.359.
To determine whether parenchymal cells or hepatic cytochrome P450 protein was changed in chronic liver diseases, and to compare the difference of CYP3A4 enzyme and its gene expression between patients with hepatic cirrhosis and obstructive jaundice, and to investigate the pharmacologic significance behind this difference.
Liver samples were obtained from patients undergoing hepatic surgery with hepatic cirrhosis (n=6) and obstructive jaundice (n=6) and hepatic angeioma (controls, n=6). CYP3A4 activity and protein were determined by Nash and western blotting using specific polychonal antibody, respectively. Total hepatic RNA was extracted and CYP3A4cDNA probe was prepared according the method of random primer marking, and difference of cyp3a4 expression was compared among those patients by Northern blotting.
Compared to control group, the CYP3A4 activity and protein in liver tissue among patients with cirrhosis were evidently reduced. (P<0.01) Northern blot showed the same change in its mRNA levels. In contrast, the isoenzyme and its gene expression were not changed among patients with obstructive jaundice.
Hepatic levels of P450s and its CYP3A4 isoform activity were selectively changed in different chronic liver diseases. CYP3A4 isoenzyme and its activity declined among patients with hepatic cirrhosis as expression of cyp3a4 gene was significantly reduced. Liver's ability to eliminate many clinical therapeutic drug substrates would decline consequently. These findings may have practical implications for the use of drugs in patients with cirrhosis and emphasize the need to understand the metabolic fate of therapeutic compounds. Elucidation of the reasons for these different changes in hepatic CYP3A4 may provide insight into more fundamental aspects and mechanisms of imparied liver function.
确定慢性肝病中实质细胞或肝细胞色素P450蛋白是否发生变化,比较肝硬化患者与梗阻性黄疸患者之间CYP3A4酶及其基因表达的差异,并探讨这种差异背后的药理学意义。
从接受肝脏手术的肝硬化患者(n = 6)、梗阻性黄疸患者(n = 6)和肝血管瘤患者(对照组,n = 6)获取肝脏样本。分别采用Nash法和使用特异性多克隆抗体的western印迹法测定CYP3A4活性和蛋白。提取肝脏总RNA,按照随机引物标记法制备CYP3A4 cDNA探针,通过Northern印迹法比较这些患者中cyp3a4表达的差异。
与对照组相比,肝硬化患者肝组织中的CYP3A4活性和蛋白明显降低(P<0.01)。Northern印迹显示其mRNA水平有相同变化。相比之下,梗阻性黄疸患者中同工酶及其基因表达未发生变化。
在不同的慢性肝病中,肝脏P450s水平及其CYP3A4同工型活性发生了选择性改变。肝硬化患者中CYP3A4同工酶及其活性下降,因为cyp3a4基因的表达显著降低。肝脏消除许多临床治疗药物底物的能力将因此下降。这些发现可能对肝硬化患者的用药具有实际意义,并强调需要了解治疗性化合物的代谢命运。阐明肝脏CYP3A4这些不同变化的原因可能有助于深入了解肝功能受损的更基本方面和机制。